Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gracell Biotechnologies stock

Own Gracell Biotechnologies stock in just a few minutes.

Gracell Biotechnologies Inc is a biotechnology business based in the US. Gracell Biotechnologies shares (GRCL) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Gracell Biotechnologies

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Gracell Biotechnologies share price

Use our graph to track the performance of GRCL stocks over time.

Gracell Biotechnologies shares at a glance

Information last updated 2021-03-10.
52-week range$19.00 - $33.70
50-day moving average $24.71
200-day moving average $24.73
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Gracell Biotechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gracell Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gracell Biotechnologies financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Gracell Biotechnologies shares

There are currently 600,436 Gracell Biotechnologies shares held short by investors – that's known as Gracell Biotechnologies's "short interest". This figure is 34.8% up from 445,290 last month.

There are a few different ways that this level of interest in shorting Gracell Biotechnologies shares can be evaluated.

Gracell Biotechnologies's "short interest ratio" (SIR)

Gracell Biotechnologies's "short interest ratio" (SIR) is the quantity of Gracell Biotechnologies shares currently shorted divided by the average quantity of Gracell Biotechnologies shares traded daily (recently around 300218). Gracell Biotechnologies's SIR currently stands at 2. In other words for every 100,000 Gracell Biotechnologies shares traded daily on the market, roughly 2000 shares are currently held short.

To gain some more context, you can compare Gracell Biotechnologies's short interest ratio against those of similar companies.

However Gracell Biotechnologies's short interest can also be evaluated against the total number of Gracell Biotechnologies shares, or, against the total number of tradable Gracell Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gracell Biotechnologies's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Gracell Biotechnologies shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Gracell Biotechnologies shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gracell Biotechnologies.

Find out more about how you can short Gracell Biotechnologies stock.

Gracell Biotechnologies share dividends

We're not expecting Gracell Biotechnologies to pay a dividend over the next 12 months.

You may also wish to consider:

Gracell Biotechnologies overview

Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC007F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate that is in Phase I clinical trial for the treatment of B-NHL. The company's product candidates also comprise GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is based in Shanghai, China. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site